semaglutide molecular structure SID 354702201 - PubChem

The difference is cost and formulation consistency, not safety or efficacy

The withdrawal of approval of rosiglitazone due to the increased risk of cardiovascular events [20] resulted in a demand for studies demonstrating cardiovascular safety for any new antidiabetic drug

Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial

A recent study published in the journal Addiction found that individuals with opioid use disorder (OUD) or alcohol use disorder (AUD) who are treated with Ozempic or similar medications for diabetes or weight-related conditions experience a 40% reduction in opioid overdose rates and a 50% reduction in alcohol intoxication compared to those with OUD and AUD who are not on these medications

Researchers call it a triple-hormone-receptor agonist